ClinicalTrials.gg
RecruitingNCT05875116Updated Aug 23, 2024

Virtual Reality Versus Constraint-induced Movement on Hemiparesis in Cerebrovascular Event

An interventional study of Virtual reality and Modified constraint-induced movement therapy in Stroke Sequelae, sponsored by Coordinación de Investigación en Salud, Mexico. Recruiting at 1 site in Mexico. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by Coordinación de Investigación en Salud, Mexico · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 8 months after the study started (first participant enrolled Aug 2018, registered May 2023).
  • Started Aug 2018; still recruiting 8 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
All
01

Study summary

The objective of this clinical trial is to measure the effect of Rehabilitation with Virtual Reality or Modified Constraint-Induced Movement Therapy on hemiparesis in patients with Cerebral Vascular Event.

The question to be answered is: What is the effect of different therapeutic modalities supported by Virtual Reality or Modified Constraint-Induced Movement Therapy compared with usual Physical and Occupational Therapy on motor recovery of paretic limbs in patients with Cerebrovascular Event?

The patients will carry out activities of:

  • Virtual reality or
  • Movement Restriction-Induction Therapy.

The investigators will compare the changes in the functionality of the paretic hemibody with a group undergoing regular physical and occupational therapy, as well as language and treatment-related satisfaction.

Read the detailed description

Patients with diagnosis of cerebrovascular event (CVE) will be recruited upon arrival at the Medical Unit in the first appointment area; The diagnosis will be verified and an appointment will be made to the office of one of the researchers -rehabilitation specialist- (evaluator 1). During the appointment the purpose of the study will be explained and doubts will be clarified. All participants, whether accept or not, will receive the consultation that is normally provided to these patients and the information will be recorded in the medical record. If the subject does not accept, after the consultation, the appropriate management for the condition will be prescribed and a subsequent appointment will be made with another corresponding doctor to continue with the control.

If the subject agrees to participate, a clinical summary will be prepared, which will include demographic data, employment situation, the need for temporary disability for work and clinical data for the research file. The signature of the informed consent letter will also be requested. This physician 1 will assign the therapeutic modality using a table of random numbers to: Group 1. Therapy supported by virtual reality; Group 2. Modified Constraint-Induced Movement Therapy; o Group 3. Usual physical and occupational therapy. The activities corresponding to each group will be carried out during 2 sessions a week, of 1 hour each session, for 6 weeks.

An appointment will be made to be assessed by the second rehabilitation specialist (evaluator 2), who will remain blind to the treatment, and will measure the functionality of the thoracic and pelvic limbs with the different scales (Fugl-Meyer, Motor Index and Fine Clamp Test), including muscle tone, trophism, arcs of mobility, functionality of the limbs, as well as of the hand, coordination, balance and sensory aspects. These scales will be applied before (initial assessment -A.I.-), during (intermediate assessment -Int.A.- week 3, session 6) and after (final assessment -F.A. - week 6, session 12) of the different rehabilitation programs. During the same times, the Boston Aphasia Intensity scale and the Intrinsic Motivation Inventory will be applied by a neuropsychologist blinded to the treatment, for the evaluation of language and satisfaction, respectively.

02

Conditions studied

  • Stroke Sequelae

Keywords

  • Constraint-induced movement therapy
  • Hemiparesis
  • Neurorehabilitation
  • Satisfaction
  • Stroke
  • Virtual Reality
03

In context

Paresis

473 studies on the registry are indexed under Paresis; 121 are open to participants now.

This study's planned enrollment of 119 is above the median of 36 across 425 interventional studies indexed under Paresis.

Browse Paresis studies →

Lead sponsor

Coordinación de Investigación en Salud, Mexico is the lead sponsor of 98 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients between 35 and 70 years of age and with a clinically and tomographically proven diagnosis of a cerebral vascular event in the territory of the middle cerebral artery.
  • Patients with hemiparesis secondary to the cerebrovascular event
  • Patients with a maximum Ashworth of 2 and Brunnstrom of minimum 4
  • Patients with or without aphasia
  • Patients with evolution between 1 to 3 months from hospital discharge of the cerebrovascular event
  • Patients with cerebrovascular event of any sex
  • Patients with vascular event without cognitive deficit
  • Patients who agree to participate by signing an , by them or their family member or person in charge.

Exclusion criteria

Exclusion Criteria:

  • Patients who develop dementia or neurological-psychomotor complications during the study.
  • Patients who present a new cerebrovascular event during the investigation
  • Patients who do not complete at least 90% of the program
  • Patients in whom a lack of family support or secondary gain is detected.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
119 participants (estimated)

Study arms

  • Experimental
    Group I: virtual reality activities

    The patient will practice the corresponding activities of the software indicated in the virtual reality equipment.

    Behavioral: Virtual reality

  • Experimental
    Group II: Modified Constraint-Induced Movement Therapy

    Patients will have the "healthy" upper limb fixed to the thorax with a sling and a horizontal shoulder immobilizer; The participants will practice physical and occupational therapy activities with the paretic upper limb.

    Behavioral: Modified constraint-induced movement therapy

  • Active comparator
    Group III: Usual Physical and Occupational Therapy

    The participants will practice physical and occupational therapy activities that are usually provided in the Medical Unit, without any restrictions on the upper extremities.

    Behavioral: Usual Physical and Occupational Therapy

Interventions

  • BehavioralVirtual reality

    The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.

  • BehavioralModified constraint-induced movement therapy

    Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb "attached to the chest", for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the "free" paretic arm and the "fixed" healthy arm, for 5 hours a day.

  • BehavioralUsual Physical and Occupational Therapy

    The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.

06

What researchers measure

Primary outcomes

  1. Functionality and disability of the paretic hemibody due to evento vascular cerebral (CVE) to the 3 weeks of treatment.

    The motor functionality and disability of the paretic hemibody will be evaluated with Fugl-Meyer scale, it comprises 5 dominions y 113 total items that are scored on a 3 point ordinal scale (0= cannot perform, 1=perform partially, 2= perform fully). The individual scores are summed and the assessment can show a minimum value of 0 and a maximum value of 226 points, including 66 points for the upper extremity and 34 points for the lower extremity. A higher score represents better functionality of the hemibody (less disability).

    Time frame: Fugl-Meyer scale will be administered at week 3 of follow-up (just after completing 6 rehabilitation sessions).

  2. Functionality and disability of the paretic hemibody due to cerebro vascular event (CVE) to the 6 weeks of treatment.

    The change in motor functionality and disability of the paretic hemibody will be evaluated with Fugl-Meyer scale, with 5 dominions y 113 total items that are scored on a 3 point ordinal scale (0= cannot perform, 1=perform partially, 2= perform fully). The individual scores are summed and the assessment can show a minimum value of 0 and a maximum value of 226 points, including 66 points for the upper extremity and 34 points for the lower extremity. Changes to higher score represents better functionality of the hemibody (less disability).

    Time frame: The Fugl-Meyer scale will be administered at week 6 of follow-up (just after completing the 12 rehabilitation sessions).

  3. Independency of patient with hemiparesis secondary to cerebro vascular event (CVE) to the 3 weeks of treatment.

    The motor functionality and independency of patient with paretic hemibody will be evaluated with motor index scale, it comprises 3 dominions and 5 items (two for upper limb, one to hand -grip-, and two to lower limb). In each domain can be obtained a minimum value of 0 and a maximum value of 33 points, and 1 point is added to the sum of all of them for the total qualification. A higher qualification represents a better ability to carry out activities of daily human life (greater independency).

    Time frame: Motor Index scale will be administered at week 3 of follow-up (just after completing 6 therapy sessions).

  4. Independency of patient with hemiparesis secondary to cerebro vascular event (CVE) to the 6 weeks of treatment.

    The motor functionality and independency of patient with paretic hemibody will be evaluated with motor index scale, it comprises 3 dominions and 5 items (two for upper limb, one to hand -grip-, and two to lower limb). In each domain can be obtained a minimum value of 0 and a maximum value of 33 points, and 1 point is added to the sum of all of them for the total qualification. Changes to higher qualification represents a better ability to carry out activities of daily human life (greater independency).

    Time frame: The Motor Index scale will be administered at week 6 of follow-up (just after completing the 12 therapy sessions).

  5. Realization of the fine clamp of the plegia hand due to cerebro vascular event (CVE) to the 3 weeks of treatment.

    The realization of grip of the plegia hand will be evaluated with the fine clamp test, it comprises three action for cubes take of size different (score: 0- inability to take the cube, 1- Grab with your whole hand, 2- Radial clamp or 3 finger clamp and 3- Forefinger thumb clamp). The total qualification has a minimum value of 0 and a maximum value of 9 points. A higher score represents a better performance of the clamp between the index finger and thumb of the paralyzed hand.

    Time frame: Fine clamp test will be administered at week 3 of follow-up (just after completing 6 therapy sessions).

  6. Realization of fine clamp of the plegia hand due to cerebro vascular event (CVE) to the 6 weeks of treatment.

    The realization of grip of the plegia hand will be evaluated with the fine clamp test, it comprises three action for cubes take of size different (score: 0- inability to take the cube, 1- Grab with your whole hand, 2- Radial clamp or 3 finger clamp, and 3- Forefinger thumb clamp). The total qualification has a minimum value of 0 and a maximum value of 9 points. A higher score represents a better performance of the clamp between the index finger and thumb of the paralyzed hand.

    Time frame: Fine clamp test will be administered at week 6 of follow-up (just after completing 12 therapy sessions).

Secondary outcomes

  1. Level of aphasy to the 3 weeks of treatment.

    The quality of language will be evaluated with the Boston Aphasia Intensity scale in patients after cerebro vascular event (CVE). In the Boston Aphasia Intensity scale the result has a minimum value of 0 and a maximum value of 5 points. A higher score represents a better language quality (less aphasy).

    Time frame: Boston Aphasia Intensity scale will be administered at week 3 of follow-up (just after completing 6 rehabilitation sessions).

  2. Level of aphasy to the 6 weeks of treatment.

    The quality of language will be evaluated with the Boston Aphasia Intensity scale in patients after cerebro vascular event (CVE). In the Boston Aphasia Intensity scale the result has a minimum value of 0 and a maximum value of 5 points. A higher score represents a better language quality (less aphasy).

    Time frame: Boston Aphasia Intensity scale will be administered at week 6 of follow-up (just after completing 12rehabilitation sessions).

  3. Level of patient satisfaction with treatment to the 3 weeks of treatment.

    The satisfaction reported by the patient with the treatment received will be evaluated, with the Intrinsic Motivation inventory. In the Intrinsic Motivation inventory the result has a minimum value of 22 and a maximum value of 154 points. Score: from 1 (no satisfaction) to 7 (maximum satisfaction). A higher score represents a best level of satisfaction

    Time frame: Intrinsic Motivation inventory will be administered at week 3 of follow-up (just after completing 6 rehabilitation sessions).

  4. Level of patient satisfaction with treatment to the 6 weeks of treatment.

    The satisfaction reported by the patient with the treatment received will be evaluated, with the Intrinsic Motivation inventory. In the Intrinsic Motivation inventory the result has a minimum value of 22 and a maximum value of 154 points. Score: from 1 (no satisfaction) to 7 (maximum satisfaction). A higher score represents a best level of satisfaction

    Time frame: Intrinsic Motivation inventory will be administered at week 6 of follow-up (just after completing 12 rehabilitation sessions).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Aug 2024, 72 months.

Of 223 non-industry interventional studies with no phase under Paresis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 55. This study's 72 months is above that.

Counting every sponsor, half of 241 studies reached it within 32 months; a quarter within 13 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2023
First posted
May 25, 2023
StartActual
Aug 17, 2018
Primary completionActual
Aug 21, 2024
CompletionEst.
Aug 21, 2024
Last update
Aug 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05875116
Lead sponsor
Coordinación de Investigación en Salud, Mexico
Responsible party
María del Carmen Rojas-Sosa (Principal Investigator, Coordinación de Investigación en Salud, Mexico) — Principal investigator
First posted
May 25, 2023
Start date
Aug 17, 2018
Primary completion
Aug 21, 2024
Completion
Aug 21, 2024 (estimated)
Last update
Aug 23, 2024

Study contacts

Juan Garduño-Espinosa, Doctorado
Contact
juan.gardunoe@gmail.com
55 5228 9917 ext. 4314
María del Carmen Rojas-Sosa, Doctorado
Contact
mc_rojass@yahoo.com.mx
5521090980
María del Carmen Rojas-Sosa, Doctorado
principal investigator · Instituto Mexicano del Seguro Social

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion